BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

ABSTRACT:

Background

Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted therapies for PeM exist. Some immune checkpoint inhibitor studies of mesothelioma have found positivity to be associated with a worse prognosis.

Methods

To search for novel therapeutic targets for PeM, we performed a comprehensive integrative multi-omics analysis of the genome, transcriptome, and proteome of 19 treatment-naïve PeM, and in particular, we examined BAP1 mutation and copy number status and its relationship to immune checkpoint inhibitor activation.

Results

We found that PeM could be divided into tumors with an inf

SUBMITTER: Shrestha R 

PROVIDER: S-EPMC6378747 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature